Sexual MedicineMolecular Mechanisms of Vacuum Therapy in Penile Rehabilitation: A Novel Animal Study
Introduction
Prostate cancer is the most common solid-organ cancer in men and one of the leading causes of death [1]. With early detection and radical prostatectomy (RP), the 15-yr overall, actuarial, cancer-specific survival rate has reached 90% [2], [3]. Unfortunately, RP is associated with at least transient erectile dysfunction (ED), with ED rates ranging from 20% to 90% depending upon the study reviewed [1], [2], [3], [4]. It is postulated that the development of post-RP ED is due predominantly to a combination of temporary cavernous nerve (CN) injury and damage to the erectile tissue secondary to neuropraxia and potentially the absence of cavernosal oxygenation [5].
To improve the patients’ quality of life and the acceptance of the RP, penile rehabilitation (PR) after RP is now widely applied in clinical practice [3]. Currently, PR methods include the use of phosphodiesterase type 5 inhibitors, intracavernosal injection/intraurethral suppository, the vacuum erectile device (VED), or combination therapy [3].
Vacuum therapy utilizes negative pressure to distend the corporal sinusoids and to increase blood inflow to the penis. Clinical data indicated that vacuum therapy is the only PR method that may preserve penile length, improves patient and partner sexual satisfaction, and allows earlier return of spontaneous erection [3], [6]. However, its unknown mechanism hampered doctors’ recommendation and patients’ compliance [3].
To explore the underlying mechanism of VED therapy after RP, we applied our newly designed rat-specific VED [7] to the bilateral cavernous nerve crush (BCNC) rat model. The BCNC rat model is believed to simulate the neural injury that occurs during RP and is designed to study the mechanisms of ED after RP as well as to explore ED-minimizing strategies [8].
Section snippets
Animal grouping, bilateral cavernous nerve crush, and vacuum erectile device therapy
Fifteen Sprague-Dawley rats (Harlan Laboratories, Houston, TX, USA), initially weighing 200–250 g, were randomly and equally divided into three groups: (1) sham (CN expose surgery only, no nerve crushing, no VED therapy); (2) control (BCNC procedure, no VED therapy); and (3) treatment group (BCNC procedure; VED therapy beginning at 2 wk after BCNC surgery, 5 min twice daily with a 1 min interval, Monday–Friday, total VED treatment time: 4 wk). The BCNC procedure was reported previously [8]. The
Erectile function assessment
EF was assessed by tracing the ICP under the CNS, and in the meantime measuring the AP. The typical ICP tracings of sham, BCNC, and BCNC with daily VED therapy are shown in Fig. 1A–C. The analysis is presented in ICP/MAP ratios and AUCs (Fig. 1D and E). The ICP/MAP ratios in the sham group were 0.61 ± 0.02 at 5.0 V and 0.71 ± 0.03 at 7.5 V, which were significantly higher compared with all other groups (p < 0.01). BCNC dramatically decreased the ICP/MAP ratios: 0.25 ± 0.02 at 5 V and 0.32 ± 0.03 at 7.5 V.
Discussion
The rat BCNC as an RP-induced ED model has been widely accepted in PR research. It was first reported by Quinlan et al in 1989 and documented in prior experiments using this animal model in the assessment of functional and structural changes of erectile tissue under various interventions [8]. Our study showed a dramatic reduction in ICP/MAP ratios and AUC in animals after BCNC when compared with the sham group. The reduced ICP/MAP ratios and AUC were associated with significantly reduced smooth
Conclusions
We have demonstrated that VED therapy in the BCNC model preserves EF and acts by preserving smooth muscle content and endothelial integrity via antihypoxia, antiapoptosis, and antifibrosis mechanisms. The daily VED therapy effect on EF recovery is consistent with patients’ results and without significant side effects. This scientific evidence, although from an animal model, may motivate physicians’ recommendations and improve patients’ compliance in the clinical setting.
References (30)
- et al.
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience
Urol Clin North Am
(2001) Penile rehabilitation after radical prostatectomy: where do we stand and where are we going?
J Sex Med
(2007)Erectile dysfunction following treatment of prostate cancer: new insights and therapeutic options
J Mens Health Gen
(2004)- et al.
Design and application of a new rat-specific vacuum erectile device for penile rehabilitation research
J Sex Med
(2009) - et al.
Functional sequelae of cavernous nerve injury in the rat: is there model dependency
J Sex Med
(2006) - et al.
The functional and structural consequences of cavernous nerve injury are ameliorated by sildenafil citrate
J Sex Med
(2008) - et al.
Apoptosis in the rat penis after penile denervation
J Urol
(1997) - et al.
Penile weight and cell subtype specific changes in post-radical prostatectomy model of erectile dysfunction
J Urol
(2003) Prevention and management of erectile dysfunction following radical prostatectomy
Urol Clin North Am
(2001)- et al.
Erectile dysfunction after radical prostatectomy: hemodynamic profiles and their correlation with the recovery of erectile function
J Urol
(2002)
PGE1 suppresses the induction of collagen synthesis by transforming growth factor-beta 1 in human corpus cavernosum smooth muscle
J Urol
Fibrosis and loss of smooth muscle in the corpora cavernosa precede corporal veno-occlusive dysfunction (CVOD) induced by experimental cavernosal nerve damage in the rat
J Sex Med
Quality-of-life outcomes in men treated for localized prostate cancer
JAMA
Cited by (82)
Reviving intimacy: Penile rehabilitation strategies for men after prostate cancer treatment
2023, Prostate InternationalEmerging Roles of Penile Traction Therapy and Vacuum Erectile Devices
2022, Sexual Medicine ReviewsFrench Urological Association (AFU) guidelines for Peyronie's disease assessment and treatment
2021, Progres en Urologie